as 12-20-2024 4:00pm EST
Stocks
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
Founded: | 2008 | Country: | Israel |
Employees: | N/A | City: | RAMAT GAN |
Market Cap: | 5.2M | IPO Year: | N/A |
Target Price: | $1.00 | AVG Volume (30 days): | 1.3M |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -81.80 | EPS Growth: | N/A |
52 Week Low/High: | $0.21 - $13.56 | Next Earning Date: | 11-14-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
SLXN Breaking Stock News: Dive into SLXN Ticker-Specific Updates for Smart Investing
TipRanks
3 days ago
Business Wire
3 days ago
GlobeNewswire
4 days ago
GlobeNewswire
10 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
ACCESSWIRE
a month ago
ACCESSWIRE
2 months ago
The information presented on this page, "SLXN BIOMOTION SCIENCES - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.